Sanofi and Regeneron's Dupixent scores in Europe as the first biologic to treat COPD

After more than a decade with no treatment advances for chronic obstructive pulmonary disease (COPD), two have been approved by regulators on either side of the Atlantic within a week.

Wednesday, the European Medicines Agency (EMA) signed off on Regeneron and Sanofi’s anti-inflammatory blockbuster Dupixent to treat COPD, which restricts airflow from the lungs and leaves patients struggling to breathe.